A Phase 2 interventional study of Azacitidine and Durvalumab in Leukemia, Myeloid, Acute and Myelodysplastic Syndromes, sponsored by Celgene. Completed at 103 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-28.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Leukemia, Myeloid, Acute by Bristol-Myers Squibb — 1 open to participants now, 4 under way, none of them phase 3. Leukemia, Myeloid, Acute · Bristol-Myers Squibb.
Among the 43 studies in Leukemia, Myeloid, Acute by Bristol-Myers Squibb, this one is the 4th largest by enrollment of the 30 interventional ones that give a count, is one of 5 that started in 2016, is one of 8 in phase 2, and was the 23rd registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 813 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →1 of the 43 studies in Leukemia, Myeloid, Acute by Bristol-Myers Squibb is open now, in 1 country. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 621 Leukemia, Myeloid, Acute studies recruiting now, 361 (58%) set no upper age limit and 220 (35%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 12 · Phase 3 2
First in 2006; this study’s year is marked. 5 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 213 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 38 across the 30 interventional studies, 151 across the 11 observational. Of the 36 that completed or were terminated, 9 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
1 of the studies in Leukemia, Myeloid, Acute by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06073769Bristol-Myers SquibbA Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia | 2027-07-30 |
Add it to your calendar (.ics) → With an account.
Among the 43 studies in Leukemia, Myeloid, Acute by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to evaluate the efficacy of subcutaneous azacitidine in combination with durvalumab as compared with subcutaneous azacitidine alone in adults with previously untreated, higher risk MDS who are not eligible for HSCT or in adults ≥ 65 years old with previously untreated AML who are not eligible for HSCT, with intermediate or poor cytogenetic risk.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For both cohorts:
Female subjects of may participate, providing they meet the following conditions:
Male subject must:
Willing and able to adhere to the study visit schedule and other protocol requirements.
MDS Cohort:
Central confirmation of the categorization of the MDS risk classification, as per the Revised - International prognostic scoring system (IPSS-R) Intermediate risk with >10% blasts or poor or very poor cytogenetics, or IPSS-R High or Very High risk (results of central pathology review required prior to receiving the first dose of IP).
Acute myeloid leukemia (AML) Cohort:
Central confirmation of diagnosis of one of the following untreated AML as per WHO classification:
Exclusion Criteria:
For both cohorts:
Use of any of the following within 28 days prior to the first dose of IP:
Prior history of (except MDS for AML subjects), unless the subject has been free of the disease for ≥ 2 years. However, subjects with the following history/concurrent conditions are allowed:
Subject has active or prior documented or inflammatory disorders (including inflammatory bowel disease [eg, colitis, Crohn's disease], diverticulitis with the exception of a prior episode that has resolved or diverticulosis, celiac disease, irritable bowel disease [exclude only if active within the last 6 months prior to signing the ICF], or other serious gastrointestinal chronic conditions associated with diarrhea; systemic lupus erythematosus; Wegener's syndrome [granulomatosis with polyangiitis]; myasthenia gravis; Graves' disease; rheumatoid arthritis; hypophysitis, uveitis; etc) within the past 3 years prior to the start of treatment. The following are exceptions to this criterion:
Significant active cardiac disease within the previous 6 months prior to signing the ICF, including:
Current or prior use of medication within 14 days prior to the first dose of IP. The following are exceptions to this criterion:
Any of the following laboratory abnormalities:
MDS Cohort:
Absolute white blood cell (WBC) count ≥ 15 × 10\^9/L.
AML Cohort:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 75 mg/m² subcutaneous azacitidine for 7 days every 4 weeks (Q4W) in combination with 1500 mg intravenous durvalumab on Day 1 of every 4 week cycle for at least 6 cycles. Participants who benefited from treatment may have continued treatment until loss of that benefit, disease progression or other treatment discontinuation criterion were met.
Drug: Azacitidine · Biological: Durvalumab
Participants received 75 mg/m² subcutaneous azacitidine for 7 days every 4 weeks for at least 6 cycles. Participants who benefited from treatment may have continued treatment until loss of that benefit, disease progression or other treatment discontinuation criterion were met.
Drug: Azacitidine
Administered by subcutaneous injection on Days 1 to 7 of each 4-week treatment cycle.
Administered by intravenous infusion on Day 1 of every 4-week treatment cycle.
Also known as: MEDI4736
MDS Cohort: Overall Response Rate
Overall response rate (ORR) is defined as the percentage of participants achieving a complete remission (CR), partial remission (PR), marrow complete remission (mCR), and/or hematological improvement (HI) based on International Working Group (IWG) 2006 response criteria for MDS and central review. CR: ≤ 5% myeloblasts in bone marrow (BM), and peripheral blood: hemoglobin ≥ 11 g/dL; platelets ≥ 100 × 10⁹/L; neutrophils ≥ 1.0 × 10⁹/L; blasts 0% PR: BM blasts decreased by ≥ 50% but still \> 5%; peripheral blood as for CR mCR: BM ≤ 5% myeloblasts and decrease by ≥ 50% HI: Any of the following: •Hemoglobin increase by ≥ 1.5 g/dL or reduction of units of red blood cell (RBC) transfusions of at least 4 RBC transfusions/8 weeks compared with pretreatment •Absolute increase in platelets of ≥ 30 × 10⁹/L if pretreatment value \> 20 × 10⁹/L or increase from \< 20 × 10⁹/L to \> 20 × 10⁹/L and by at least 100% •At least 100% increase in neutrophils and an absolute increase of \> 0.5 × 10⁹/L
Time frame: Response was assessed following every 3 treatment cycles until treatment discontinuation; median duration of treatment was 239 days (AZA) and 215 days (DUR) in the AZA + DUR group and 210 days in the AZA alone group.
AML Cohort: Overall Response Rate
Overall response rate for AML is defined as the percentage of participants achieving an overall response of morphologic complete remission (CR) or morphologic complete remission with incomplete blood count recovery (CRi) based on modified IWG 2003 response criteria for AML and central review. CR: The following conditions must be met: •Absolute neutrophil count (ANC) ≥ 1.0 x10⁹/L •Platelet count ≥ 100 x10⁹/L •The bone marrow should contain less than 5% blast cells; •Auer rods should not be detectable; •No platelet, or whole blood transfusions for 7days prior to the date of the hematology assessment. CRi: Defined as a morphologic complete remission but the ANC count may be \< 1.0 x10⁹/L and/or the platelet count may be \< 100 x10⁹/L.
Time frame: Response was assessed following every 3 treatment cycles until treatment discontinuation; median duration of treatment was 198 days (AZA) and 171 days (DUR) in the AZA + DUR group and 203 days in the AZA alone group.
MDS Cohort: Kaplan Meier Estimate of Time to First Response
Time to first response is defined as the time from randomization to the earliest date any response (complete remission (CR), partial remission (PR), marrow complete remission (mCR), and/or hematological improvement (HI)) based on International Working Group (IWG) 2006 response criteria for MDS and central review. Participants who did not achieve any defined response were censored at the date of last adequate response assessment, disease progression, or death, whichever occurred first. Response was assessed following every 3 treatment cycles until treatment discontinuation.
Time frame: From randomization to the earliest date any response (up to approximately 34 months)
MDS Cohort: Kaplan Meier Estimate of Relapse-free Survival
Relapse-free survival is defined as the time from the date of first documented response (complete remission (CR), partial remission (PR)) to the date of disease relapse or death from any cause, whichever occurred first according to the International Working Group (IWG) 2006 response criteria for MDS and central review. Participants who were still alive and progression-free were censored at the date of their last response assessment. Participants who received a subsequent therapy before the date of disease relapse or death were censored at the time of subsequent therapy. Relapse after CR or PR is defined as at least one of the following: •Return to pretreatment bone marrow blast % •Decrement of ≥ 50% from maximum remission/response levels in granulocytes or platelets •Reduction in hemoglobin concentration by ≥ 1.5 g/dL or transfusion dependence. Response was assessed following every 3 treatment cycles until treatment discontinuation.
Time frame: From randomization to to the date of disease relapse or death from any cause, whichever occurred first (up to approximately 34 months)
MDS Cohort: Percentage of Participants Who Achieved a Cytogenetic Response
Cytogenetic response is defined as the percentage of participants who achieved a complete cytogenetic response or partial cytogenetic response according to the International Working Group (IWG) 2006 response criteria and central review. Complete cytogenetic response: Disappearance of the baseline chromosomal abnormality without appearance of new abnormalities. Partial cytogenetic response: At least 50% reduction of the chromosomal abnormality. Response was assessed following every 3 treatment cycles until treatment discontinuation.
Time frame: From randomization up to approximately 34 months
MDS Cohort: Kaplan-Meier Estimate of Progression-free Survival (PFS)
Progression-free survival is defined as the time from randomization to the first documented progressive disease (PD), relapse, or death due to any cause during or after the treatment period, whichever occurred first, according to the International Working Group (IWG) 2006 response criteria for MDS and central review. Participants who were still alive and progression-free were censored at the date of their last response assessment. Progressive disease is defined as follows: - an increase in BM blasts relative to nadir: •If nadir less than 5% blasts: ≥ 50% increase in blasts to \> 5% blasts •If nadir 5% - 10% blasts: ≥ 50% increase in blasts to \> 10% blasts •If nadir 10% - 20% blasts: ≥ 50% increase in blasts to \> 20% blasts •If nadir 20% - 30% blasts: ≥ 50% increase in blasts to \> 30% blasts And any of the following: •At least 50% decrement from maximum remission/response levels in granulocytes or platelets •Reduction in Hgb concentration by ≥ 2 g/dL •Transfusion dependence
Time frame: From randomization to the first documented progressive disease (PD), relapse, or death due to any cause (up to approximately 34 months)
MDS Cohort: Kaplan-Meier Estimate of Duration of Response
Duration of response is defined as the time from when the first overall response (complete remission (CR), partial remission (PR), marrow complete remission (mCR), and/or hematological improvement (HI)) was observed until relapse, progressive disease (PD), or death, as defined by the International Working Group (IWG) 2006 response criteria and central review. If no relapse, PD, or death was observed, the duration of response was censored at the last response assessment date that the participant was known to be progression-free. Response was assessed following every 3 treatment cycles until treatment discontinuation.
Time frame: From randomization to the first overall response, or death (up to approximately 34 months)
MDS Cohort: Kaplan-Meier Estimate of Time to AML Transformation
Participants were monitored for transformation to acute myeloid leukemia (AML) until death, lost to follow-up, withdrawal of consent for further data collection, or the end of the trial. Time to transformation to AML is defined as the time from the date of randomization until the date the participant had documented transformation to AML (defined as at least 30% of myeloblasts in the bone marrow). Participants with no transformation to AML were censored at the date of their last disease assessment.
Time frame: From randomization to the date the participant had documented transformation to AML (up to approximately 34 months)
MDS Cohort: Percentage of Participants With Disease Transformation to AML
Disease transformation to acute myeloid leukemia (AML) is defined as at least 30% myeloblasts in the bone marrow. Participants were monitored for transformation to AML until death, lost to follow-up, withdrawal of consent for further data collection, or the end of the trial. Participants with no transformation to AML were censored at the date of their last disease assessment.
Time frame: From randomization until death, lost to follow-up, withdrawal of consent for further data collection, or the end of the trial (up to approximately 34 months)
AML Cohort: Kaplan Meier Estimate of Time to First Response
Time to first response is defined as the time between the date of randomization and the earliest date any response (CR or CRi) was observed based on the modified International Working Group (IWG) 2003 response criteria for AML and central review. Participants who did not achieve any defined response were censored at the date of last adequate response assessment, disease progression, or death, whichever occurred first. Response was assessed following every 3 treatment cycles until treatment discontinuation.
Time frame: From randomization and the earliest date any response (up to approximately 34 months)
AML Cohort: Kaplan Meier Estimate of Relapse-free Survival
Relapse-free survival is defined as time from the date of first documented response (morphologic complete remission (CR) or morphologic complete remission with incomplete blood count recovery (CRi)) to the date of disease relapse or death from any cause, whichever occurred first based on the modified International Working Group (IWG) 2003 response criteria for AML and central review. Participants who were still alive and progression-free were censored at the date of their last response assessment. Participants who received a subsequent therapy before the date of disease relapse or death were censored at the time of subsequent therapy.
Time frame: From randomization to the date of disease relapse or death from any cause, whichever occurred first (up to approximately 34 months)
AML Cohort: Percentage of Participants Who Achieved a Complete Cytogenetic Response
Complete cytogenetic response (CyCR) based on the modified International Working Group (IWG) 2003 response criteria is defined as morphologic complete remission with a reversion to a normal karyotype. The following conditions must be met: • Absolute neutrophil count (ANC) ≥ 1.0 x10⁹/L • Platelet count ≥ 100 x10⁹/L • The bone marrow should contain less than 5% blast cells; • Auer rods should not be detectable; • No platelet, or whole blood transfusions for 7days prior to the date of the hematology assessment. AND • Reversion to normal karyotype at time of CR (based on ≥ 10 metaphases). Response was assessed following every 3 treatment cycles until treatment discontinuation.
Time frame: From randomization up to approximately 34 months)
AML Cohort: Percentage of Participants With Hematologic Improvement
Hematological improvement was defined as participants with a erythroid response (HI-E), platelet response (HI-P) or neutrophil response (HI-NE) for at least 8 weeks, according to the IWG 2006 response criteria: Hi-E (in participants with pretreatment hemoglobin \< 11 g/dL or red blood cell (RBC)-transfusion dependent): Hemoglobin increase of ≥ 1.5 g/dL, or reduction in units of RBC transfusions of at least 4 RBC transfusions/8 weeks compared with the 8 weeks prior to pretreatment. HI-P (in participants with pretreatment platelet count \< 100 × 10⁹/L): Absolute increase in platelets of ≥ 30 × 10⁹/L if pretreatment value \> 20 × 10⁹/L or increase from \< 20 × 10⁹/L to \> 20 × 10⁹/L and by at least 100%. HI-N (in participants with pretreatment neutrophils \< 1.0 × 10⁹/L): At least 100% increase in neutrophils and an absolute increase of \> 0.5 × 10⁹/L. Response was assessed following every 3 treatment cycles until treatment discontinuation.
Time frame: From randomization up to approximately 34 months
AML Cohort: Kaplan-Meier Estimate of Duration of Response
Duration of response is defined as the time from the first response morphologic complete remission (CR) or morphologic complete remission with incomplete blood count recovery (CRi)) was observed until relapse, PD, or death based on the IWG 2003 response criteria and central review. If no relapse, PD, or death was observed, the duration of response was censored at the last response assessment date that the participant was known to be progression-free. Response was assessed following every 3 treatment cycles until treatment discontinuation.
Time frame: From randomization until relapse, PD, or death (up to approximately 34 months)
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Treatment emergent adverse events are adverse events (AEs) that occurred or worsened on or after the first dose of study drug (durvalumab or azacitidine) and within 90 days after last dose of durvalumab or 28 days after last dose of azacitidine. A treatment-related TEAE is a TEAE where the causal relationship was assessed by the investigator as "Suspected". The intensity of AEs was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03: Grade 1 (Mild): asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 (Moderate): minimal, local or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death due to AE.
Time frame: From first dose to 90 days after last dose of durvalumab or 28 days after last dose of azacitidine proir to the extension study (up to approximately 34 months)
Kaplan-Meier Estimate of Overall Survival
Overall survival is defined as the time between randomization and death/censored date. Participants who were alive at the time of the clinical data cut-off were censored at the last known alive date.
Time frame: From randomization to date of death or last known alive date (up to approximately 34 months)
One-year Survival
One-year survival is defined as the probability of survival at 1 year from randomization and is represented by the Kaplan-Meier estimate of the percentage of participants alive after 1 year.
Time frame: At 12 months after randomization
Durvalumab Serum Concentration
Time frame: Cycle 1 Day 1 end of infusion (EOI), Cycle 2 Day 1 pre-infusion, Cycle 4 Day 1 pre-infusion and EOI, and Cycle 6 Day 1 pre-infusion
Change From Baseline in Selected Hematology Parameters I
Baseline values are defined as the last assessment of a particular parameter prior to administration of the participants first dose.
Time frame: Baseline and last lab measurement collected in Cycle 2 (Last measurement could be taken either on Day 1, 8, 15 or 22)
Change From Baseline in Selected Hematology Parameters II
Baseline values are defined as the last assessment of a particular parameter prior to administration of the participants first dose.
Time frame: Baseline and last lab measurement collected in Cycle 2 (Last measurement could be taken either on Day 1, 8, 15 or 22)
Change From Baseline in Selected Chemistry Parameters I
Baseline values are defined as the last assessment of a particular parameter prior to administration of the participants first dose.
Time frame: Baseline and last lab measurement collected in Cycle 2 (Last measurement could be taken either on Day 1, 8, 15 or 22)
Change From Baseline in Selected Chemistry Parameters II
Baseline values are defined as the last assessment of a particular parameter prior to administration of the participants first dose.
Time frame: Baseline and last lab measurement collected in Cycle 2 (Last measurement could be taken either on Day 1, 8, 15 or 22)
Change From Baseline in Selected Chemistry Parameters III
Baseline values are defined as the last assessment of a particular parameter prior to administration of the participants first dose.
Time frame: Baseline and last lab measurement collected in Cycle 2 (Last measurement could be taken either on Day 1, 8, 15 or 22)
Change From Baseline in Selected Chemistry Parameters IV
Baseline values are defined as the last assessment of a particular parameter prior to administration of the participants first dose.
Time frame: Baseline and last lab measurement collected in Cycle 2 (Last measurement could be taken either on Day 1, 8, 15 or 22)
This study consisted of 2 cohorts: • Adults with previously untreated intermediate, high or very high risk myelodysplastic syndromes (MDS) not eligible for hematopoietic stem cell transplantation (HSCT). • Adults with previously untreated acute myeloid leukemia (AML) ≥ 65 years and not eligible for HSCT with intermediate or poor cytogenetic risk.
| Milestone | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone |
|---|---|---|---|---|
| Started | 42 | 42 | 64 | 65 |
| Completed | 4 | 1 | 1 | 5 |
| Not completed | 38 | 41 | 63 | 60 |
| Withdrew: Death | 7 | 11 | 12 | 11 |
| Withdrew: Adverse event | 0 | 1 | 12 | 3 |
| Withdrew: Progressive disease | 15 | 14 | 30 | 20 |
| Withdrew: Lack of efficacy | 2 | 2 | 2 | 6 |
| Withdrew: Withdrawal by subject | 7 | 5 | 5 | 8 |
| Withdrew: Other reasons | 7 | 8 | 2 | 12 |
Overall response rate (ORR) is defined as the percentage of participants achieving a complete remission (CR), partial remission (PR), marrow complete remission (mCR), and/or hematological improvement (HI) based on International Working Group (IWG) 2006 response criteria for MDS and central review. CR: ≤ 5% myeloblasts in bone marrow (BM), and peripheral blood: hemoglobin ≥ 11 g/dL; platelets ≥ 100 × 10⁹/L; neutrophils ≥ 1.0 × 10⁹/L; blasts 0% PR: BM blasts decreased by ≥ 50% but still \> 5%; peripheral blood as for CR mCR: BM ≤ 5% myeloblasts and decrease by ≥ 50% HI: Any of the following: •Hemoglobin increase by ≥ 1.5 g/dL or reduction of units of red blood cell (RBC) transfusions of at least 4 RBC transfusions/8 weeks compared with pretreatment •Absolute increase in platelets of ≥ 30 × 10⁹/L if pretreatment value \> 20 × 10⁹/L or increase from \< 20 × 10⁹/L to \> 20 × 10⁹/L and by at least 100% •At least 100% increase in neutrophils and an absolute increase of \> 0.5 × 10⁹/L
| percentage of participants | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone |
|---|---|---|
| MDS Cohort: Overall Response Rate | 61.9 (47.22 to 76.59) | 47.6 (32.51 to 62.72) |
Overall response rate for AML is defined as the percentage of participants achieving an overall response of morphologic complete remission (CR) or morphologic complete remission with incomplete blood count recovery (CRi) based on modified IWG 2003 response criteria for AML and central review. CR: The following conditions must be met: •Absolute neutrophil count (ANC) ≥ 1.0 x10⁹/L •Platelet count ≥ 100 x10⁹/L •The bone marrow should contain less than 5% blast cells; •Auer rods should not be detectable; •No platelet, or whole blood transfusions for 7days prior to the date of the hematology assessment. CRi: Defined as a morphologic complete remission but the ANC count may be \< 1.0 x10⁹/L and/or the platelet count may be \< 100 x10⁹/L.
| percentage of participants | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone |
|---|---|---|
| AML Cohort: Overall Response Rate | 31.3 (19.89 to 42.61) | 35.4 (23.76 to 47.01) |
Time to first response is defined as the time from randomization to the earliest date any response (complete remission (CR), partial remission (PR), marrow complete remission (mCR), and/or hematological improvement (HI)) based on International Working Group (IWG) 2006 response criteria for MDS and central review. Participants who did not achieve any defined response were censored at the date of last adequate response assessment, disease progression, or death, whichever occurred first. Response was assessed following every 3 treatment cycles until treatment discontinuation.
| Weeks | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone |
|---|---|---|
| MDS Cohort: Kaplan Meier Estimate of Time to First Response | 14.3 (11.3 to 20.9) | 18.4 (8.1 to 26.1) |
Relapse-free survival is defined as the time from the date of first documented response (complete remission (CR), partial remission (PR)) to the date of disease relapse or death from any cause, whichever occurred first according to the International Working Group (IWG) 2006 response criteria for MDS and central review. Participants who were still alive and progression-free were censored at the date of their last response assessment. Participants who received a subsequent therapy before the date of disease relapse or death were censored at the time of subsequent therapy. Relapse after CR or PR is defined as at least one of the following: •Return to pretreatment bone marrow blast % •Decrement of ≥ 50% from maximum remission/response levels in granulocytes or platelets •Reduction in hemoglobin concentration by ≥ 1.5 g/dL or transfusion dependence. Response was assessed following every 3 treatment cycles until treatment discontinuation.
| Months | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone |
|---|---|---|
| MDS Cohort: Kaplan Meier Estimate of Relapse-free Survival | 3.7 (3.0 to NA) | NA (0.0 to NA) |
Cytogenetic response is defined as the percentage of participants who achieved a complete cytogenetic response or partial cytogenetic response according to the International Working Group (IWG) 2006 response criteria and central review. Complete cytogenetic response: Disappearance of the baseline chromosomal abnormality without appearance of new abnormalities. Partial cytogenetic response: At least 50% reduction of the chromosomal abnormality. Response was assessed following every 3 treatment cycles until treatment discontinuation.
| percentage of participants | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone |
|---|---|---|
| MDS Cohort: Percentage of Participants Who Achieved a Cytogenetic Response | 47.6 (26.26 to 68.98) | 34.8 (15.32 to 54.25) |
Progression-free survival is defined as the time from randomization to the first documented progressive disease (PD), relapse, or death due to any cause during or after the treatment period, whichever occurred first, according to the International Working Group (IWG) 2006 response criteria for MDS and central review. Participants who were still alive and progression-free were censored at the date of their last response assessment. Progressive disease is defined as follows: - an increase in BM blasts relative to nadir: •If nadir less than 5% blasts: ≥ 50% increase in blasts to \> 5% blasts •If nadir 5% - 10% blasts: ≥ 50% increase in blasts to \> 10% blasts •If nadir 10% - 20% blasts: ≥ 50% increase in blasts to \> 20% blasts •If nadir 20% - 30% blasts: ≥ 50% increase in blasts to \> 30% blasts And any of the following: •At least 50% decrement from maximum remission/response levels in granulocytes or platelets •Reduction in Hgb concentration by ≥ 2 g/dL •Transfusion dependence
| Months | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone |
|---|---|---|
| MDS Cohort: Kaplan-Meier Estimate of Progression-free Survival (PFS) | 8.7 (5.6 to 10.2) | 8.6 (3.4 to 11.2) |
Duration of response is defined as the time from when the first overall response (complete remission (CR), partial remission (PR), marrow complete remission (mCR), and/or hematological improvement (HI)) was observed until relapse, progressive disease (PD), or death, as defined by the International Working Group (IWG) 2006 response criteria and central review. If no relapse, PD, or death was observed, the duration of response was censored at the last response assessment date that the participant was known to be progression-free. Response was assessed following every 3 treatment cycles until treatment discontinuation.
| Weeks | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone |
|---|---|---|
| MDS Cohort: Kaplan-Meier Estimate of Duration of Response | 33.9 (22.1 to 47.4) | 39.7 (26.3 to 73.1) |
Participants were monitored for transformation to acute myeloid leukemia (AML) until death, lost to follow-up, withdrawal of consent for further data collection, or the end of the trial. Time to transformation to AML is defined as the time from the date of randomization until the date the participant had documented transformation to AML (defined as at least 30% of myeloblasts in the bone marrow). Participants with no transformation to AML were censored at the date of their last disease assessment.
| Months | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone |
|---|---|---|
| MDS Cohort: Kaplan-Meier Estimate of Time to AML Transformation | 20.8 (15.0 to NA) | 27.7 (11.3 to NA) |
Disease transformation to acute myeloid leukemia (AML) is defined as at least 30% myeloblasts in the bone marrow. Participants were monitored for transformation to AML until death, lost to follow-up, withdrawal of consent for further data collection, or the end of the trial. Participants with no transformation to AML were censored at the date of their last disease assessment.
| Percentage of participants | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone |
|---|---|---|
| MDS Cohort: Percentage of Participants With Disease Transformation to AML | 23.8 | 19.0 |
Time to first response is defined as the time between the date of randomization and the earliest date any response (CR or CRi) was observed based on the modified International Working Group (IWG) 2003 response criteria for AML and central review. Participants who did not achieve any defined response were censored at the date of last adequate response assessment, disease progression, or death, whichever occurred first. Response was assessed following every 3 treatment cycles until treatment discontinuation.
| Weeks | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone |
|---|---|---|
| AML Cohort: Kaplan Meier Estimate of Time to First Response | NA (14.3 to NA) | 25.3 (13.9 to 43.0) |
Relapse-free survival is defined as time from the date of first documented response (morphologic complete remission (CR) or morphologic complete remission with incomplete blood count recovery (CRi)) to the date of disease relapse or death from any cause, whichever occurred first based on the modified International Working Group (IWG) 2003 response criteria for AML and central review. Participants who were still alive and progression-free were censored at the date of their last response assessment. Participants who received a subsequent therapy before the date of disease relapse or death were censored at the time of subsequent therapy.
| Months | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone |
|---|---|---|
| AML Cohort: Kaplan Meier Estimate of Relapse-free Survival | 9.5 (5.0 to 15.0) | 12.2 (3.5 to 19.3) |
Complete cytogenetic response (CyCR) based on the modified International Working Group (IWG) 2003 response criteria is defined as morphologic complete remission with a reversion to a normal karyotype. The following conditions must be met: • Absolute neutrophil count (ANC) ≥ 1.0 x10⁹/L • Platelet count ≥ 100 x10⁹/L • The bone marrow should contain less than 5% blast cells; • Auer rods should not be detectable; • No platelet, or whole blood transfusions for 7days prior to the date of the hematology assessment. AND • Reversion to normal karyotype at time of CR (based on ≥ 10 metaphases). Response was assessed following every 3 treatment cycles until treatment discontinuation.
| Percentage of participants | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone |
|---|---|---|
| AML Cohort: Percentage of Participants Who Achieved a Complete Cytogenetic Response | 11.3 (2.79 to 19.85) | 16.0 (5.84 to 26.16) |
Hematological improvement was defined as participants with a erythroid response (HI-E), platelet response (HI-P) or neutrophil response (HI-NE) for at least 8 weeks, according to the IWG 2006 response criteria: Hi-E (in participants with pretreatment hemoglobin \< 11 g/dL or red blood cell (RBC)-transfusion dependent): Hemoglobin increase of ≥ 1.5 g/dL, or reduction in units of RBC transfusions of at least 4 RBC transfusions/8 weeks compared with the 8 weeks prior to pretreatment. HI-P (in participants with pretreatment platelet count \< 100 × 10⁹/L): Absolute increase in platelets of ≥ 30 × 10⁹/L if pretreatment value \> 20 × 10⁹/L or increase from \< 20 × 10⁹/L to \> 20 × 10⁹/L and by at least 100%. HI-N (in participants with pretreatment neutrophils \< 1.0 × 10⁹/L): At least 100% increase in neutrophils and an absolute increase of \> 0.5 × 10⁹/L. Response was assessed following every 3 treatment cycles until treatment discontinuation.
| Percentage of participants | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone |
|---|---|---|
| AML Cohort: Percentage of Participants With Hematologic Improvement | 42.2 (30.09 to 54.29) | 38.5 (26.63 to 50.29) |
Duration of response is defined as the time from the first response morphologic complete remission (CR) or morphologic complete remission with incomplete blood count recovery (CRi)) was observed until relapse, PD, or death based on the IWG 2003 response criteria and central review. If no relapse, PD, or death was observed, the duration of response was censored at the last response assessment date that the participant was known to be progression-free. Response was assessed following every 3 treatment cycles until treatment discontinuation.
| Weeks | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone |
|---|---|---|
| AML Cohort: Kaplan-Meier Estimate of Duration of Response | 24.6 (16.4 to 48.0) | 52.0 (15.1 to 84.0) |
Treatment emergent adverse events are adverse events (AEs) that occurred or worsened on or after the first dose of study drug (durvalumab or azacitidine) and within 90 days after last dose of durvalumab or 28 days after last dose of azacitidine. A treatment-related TEAE is a TEAE where the causal relationship was assessed by the investigator as "Suspected". The intensity of AEs was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03: Grade 1 (Mild): asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 (Moderate): minimal, local or noninvasive intervention indicated; limiting age-appropriate activities of daily living. Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care. Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death due to AE.
| Participants | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone |
|---|---|---|---|---|
| Any treatment-emergent adverse event (TEAE) | 38 | 41 | 64 | 62 |
| TEAE related to DUR | 27 | — | 50 | — |
| TEAE related to AZA | 31 | 33 | 56 | 50 |
| TEAE related to DUR or AZA | 35 | 33 | 58 | 50 |
| Grade 3 TEAE | 36 | 30 | 60 | 50 |
| Grade 3 TEAE related to DUR | 18 | — | 29 | — |
| Grade 3 TEAE related to AZA | 18 | 16 | 32 | 27 |
| Grade 3 TEAE related to DUR or AZA | 22 | 16 | 38 | 27 |
| Grade 4 TEAE | 33 | 27 | 43 | 34 |
| Grade 4 TEAE related to DUR | 16 | — | 18 | — |
| Grade 4 TEAE related to AZA | 19 | 15 | 27 | 17 |
| Grade 4 TEAE related to DUR or AZA | 22 | 15 | 28 | 17 |
| Grade 5 TEAE | 10 | 9 | 26 | 11 |
| Grade 5 TEAE related to DUR | 2 | — | 1 | — |
| Grade 5 TEAE related to AZA | 1 | 1 | 1 | 1 |
| Grade 5 TEAE related to DUR or AZA | 2 | 1 | 1 | 1 |
| Serious TEAE | 34 | 29 | 56 | 45 |
| Serious TEAE related to DUR | 11 | — | 33 | — |
| Serious TEAE related to AZA | 9 | 10 | 25 | 16 |
| Serious TEAE related to DUR or AZA | 14 | 10 | 34 | 16 |
| TEAE leading to discontinuation of DUR | 5 | — | 21 | — |
| TEAE leading to discontinuation of AZA | 0 | 1 | 13 | 3 |
| TEAE leading to discontinuation of DUR or AZA | 5 | 1 | 22 | 3 |
| TEAE leading to dose reduction of AZA | 3 | 6 | 10 | 2 |
| TEAE leading to dose interruption of DUR | 24 | — | 34 | — |
| TEAE leading to dose interruption of AZA | 27 | 19 | 39 | 32 |
| TEAE leading to dose interruption of DUR or AZA | 28 | 19 | 41 | 32 |
| TEAE leading to ongoing DUR infusion interruption | 2 | — | 2 | — |
Overall survival is defined as the time between randomization and death/censored date. Participants who were alive at the time of the clinical data cut-off were censored at the last known alive date.
| Months | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone |
|---|---|---|---|---|
| Kaplan-Meier Estimate of Overall Survival | 11.6 (9.5 to NA) | 16.3 (9.8 to 22.6) | 13.0 (10.3 to 17.3) | 14.4 (10.0 to 16.6) |
One-year survival is defined as the probability of survival at 1 year from randomization and is represented by the Kaplan-Meier estimate of the percentage of participants alive after 1 year.
| Percentage of participants | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone |
|---|---|---|---|---|
| One-year Survival | 49 | 58 | 52 | 55 |
| ng/mL | MDS: Azacitidine + Durvalumab | AML: Azacitidine + Durvalumab |
|---|---|---|
| Cycle 1 Day 1 end of infusion | 375548.511 ± 140777.0558 | 378598.369 ± 201902.4363 |
| Cycle 2 Day 1 pre-infusion | 84380.032 ± 92174.3455 | 54216.956 ± 28336.3692 |
| Cycle 4 Day 1 pre-infusion | 132266.794 ± 126971.6223 | 78622.429 ± 41708.9956 |
| Cycle 4 Day 1 end of infusion | 433942.600 ± 233241.0329 | 391523.395 ± 147928.1261 |
| Cycle 6 Day 1 pre-infusion | 114448.977 ± 64608.9007 | 142517.871 ± 248212.8037 |
Baseline values are defined as the last assessment of a particular parameter prior to administration of the participants first dose.
| 10^9 cells/L | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone |
|---|---|---|---|---|
| Leukocytes (10^9/L) | -1.330 ± 2.8158 | -0.497 ± 1.1452 | -2.050 ± 9.0236 | -0.941 ± 2.7708 |
| Lymphocytes (10^9/L) | -0.242 ± 0.5314 | -0.085 ± 0.3904 | -0.394 ± 1.6995 | -0.262 ± 0.9024 |
| Neutrophils, Segmented (10^9/L) | -0.665 ± 1.6364 | -0.266 ± 0.7576 | 0.646 ± 0.7870 | -0.102 ± 0.7346 |
| Platelets (10^9/L) | 26.7 ± 112.92 | -2.6 ± 82.05 | 25.9 ± 92.86 | -0.9 ± 167.88 |
Baseline values are defined as the last assessment of a particular parameter prior to administration of the participants first dose.
| g/L | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone |
|---|---|---|---|---|
| Change From Baseline in Selected Hematology Parameters II | 2.1 ± 15.66 | 5.7 ± 18.94 | 2.2 ± 13.67 | -3.0 ± 13.91 |
Baseline values are defined as the last assessment of a particular parameter prior to administration of the participants first dose.
| g/L | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone |
|---|---|---|---|---|
| Change From Baseline in Selected Chemistry Parameters I | -1.8 ± 4.01 | -1.1 ± 2.93 | -1.8 ± 5.00 | -3.8 ± 4.78 |
Baseline values are defined as the last assessment of a particular parameter prior to administration of the participants first dose.
| U/L | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone |
|---|---|---|---|---|
| Alkaline Phosphatase (U/L) | 8.7 ± 15.71 | 4.5 ± 13.90 | 12.3 ± 55.70 | 15.5 ± 68.53 |
| Alanine Aminotransferase (U/L) | 3.6 ± 16.96 | 0.4 ± 9.40 | 0.3 ± 21.05 | 4.0 ± 19.41 |
| Aspartate Aminotransferase (U/L) | 0.9 ± 10.52 | -0.8 ± 5.73 | -0.9 ± 16.83 | 0.5 ± 14.22 |
| Lipase (U/L) | -5.4 ± 18.23 | -10.2 ± 25.80 | -2.0 ± 10.28 | 3.1 ± 42.85 |
Baseline values are defined as the last assessment of a particular parameter prior to administration of the participants first dose.
| mmol/L | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone |
|---|---|---|---|---|
| Calcium (mmol/L) | 0.004 ± 0.1013 | 0.016 ± 0.1008 | -0.003 ± 0.1523 | -0.039 ± 0.1189 |
| Glucose (mmol/L) | -0.40 ± 2.210 | -0.19 ± 1.265 | -0.38 ± 2.513 | -0.02 ± 2.365 |
| Potassium (mmol/L) | 0.15 ± 0.416 | -0.01 ± 0.451 | 0.02 ± 0.411 | 0.04 ± 0.622 |
| Sodium (mmol/L) | -0.2 ± 2.93 | 0.3 ± 3.26 | -0.6 ± 4.49 | -1.6 ± 3.73 |
Baseline values are defined as the last assessment of a particular parameter prior to administration of the participants first dose.
| umol/L | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone |
|---|---|---|---|---|
| Bilirubin (umol/L) | 2.2 ± 5.13 | 1.2 ± 4.21 | 2.4 ± 6.23 | -0.0 ± 5.31 |
| Creatinine (umol/L) | -4.0 ± 14.77 | -2.9 ± 10.19 | 2.3 ± 16.39 | -0.6 ± 15.93 |
| Urate (umol/L) | 6.8 ± 65.85 | -3.2 ± 67.06 | -15.1 ± 75.69 | -29.1 ± 80.85 |
Collected over All-cause mortality was assessed from the participants first dose to their study completion (up to approximately 66 months) SAEs and Other AEs were assessed from first dose to 90 days after last dose of durvalumab or 28 days after last dose of azacitidine (up to approximately 66 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MDS: Azacitidine + Durvalumab | 22/38 (57.9%) | 34/38 (89.5%) | 38/38 (100%) |
| MDS: Azacitidine Alone | 27/41 (65.9%) | 29/41 (70.7%) | 40/41 (97.6%) |
| AML: Azacitidine + Durvalumab | 48/64 (75%) | 56/64 (87.5%) | 63/64 (98.4%) |
| AML: Azacitidine Alone | 42/62 (67.7%) | 45/62 (72.6%) | 60/62 (96.8%) |
| Event | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone |
|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 14/38 | 9/41 | 23/64 | 14/62 |
| PneumoniaInfections and infestations | 6/38 | 3/41 | 16/64 | 8/62 |
| General physical health deteriorationGeneral disorders | 2/38 | 0/41 | 9/64 | 4/62 |
| PyrexiaGeneral disorders | 5/38 | 3/41 | 8/64 | 5/62 |
| NeutropeniaBlood and lymphatic system disorders | 4/38 | 2/41 | 3/64 | 1/62 |
| Transformation to acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/38 | 4/41 | 0/64 | 0/62 |
| AnaemiaBlood and lymphatic system disorders | 3/38 | 1/41 | 3/64 | 1/62 |
| DiarrhoeaGastrointestinal disorders | 3/38 | 1/41 | 3/64 | 1/62 |
| Urinary tract infectionInfections and infestations | 3/38 | 0/41 | 1/64 | 2/62 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 1/38 | 0/41 | 5/64 | 1/62 |
| Event | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone |
|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 23/38 | 21/41 | 20/64 | 21/62 |
| ConstipationGastrointestinal disorders | 22/38 | 20/41 | 36/64 | 33/62 |
| ThrombocytopeniaBlood and lymphatic system disorders | 19/38 | 18/41 | 24/64 | 27/62 |
| DiarrhoeaGastrointestinal disorders | 16/38 | 14/41 | 27/64 | 16/62 |
| NauseaGastrointestinal disorders | 16/38 | 11/41 | 26/64 | 22/62 |
| AnaemiaBlood and lymphatic system disorders | 14/38 | 15/41 | 19/64 | 19/62 |
| Oedema peripheralGeneral disorders | 14/38 | 7/41 | 18/64 | 9/62 |
| PyrexiaGeneral disorders | 12/38 | 13/41 | 23/64 | 21/62 |
| CoughRespiratory, thoracic and mediastinal disorders | 13/38 | 11/41 | 18/64 | 16/62 |
| AstheniaGeneral disorders | 9/38 | 14/41 | 19/64 | 12/62 |
All randomized participants (intent-to-treat population)
| Age, Continuous(years) | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone | Total |
|---|---|---|---|---|---|
| MDS | 72.5 ± 6.53 | 73.2 ± 8.83 | — | — | 72.8 ± 7.72 |
| AML | — | — | 76.2 ± 5.97 | 75.3 ± 5.36 | 75.8 ± 5.67 |
| Age, Customized(Participants) | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone | Total |
|---|---|---|---|---|---|
| MDS Cohort — < 65 years | 2 | 10 | — | — | 12 |
| MDS Cohort — ≥ 65 to < 75 years | 21 | 11 | — | — | 32 |
| MDS Cohort — ≥ 75 years | 19 | 21 | — | — | 40 |
| AML Cohort — < 65 years | — | — | 0 | 0 | 0 |
| AML Cohort — ≥ 65 to < 75 years | — | — | 24 | 28 | 52 |
| AML Cohort — ≥ 75 years | — | — | 40 | 37 | 77 |
| Sex: Female, Male(Participants) | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone | Total |
|---|---|---|---|---|---|
| MDS Cohort — Female | 14 | 12 | — | — | 26 |
| MDS Cohort — Male | 28 | 30 | — | — | 58 |
| AML Cohort — Female | — | — | 24 | 34 | 58 |
| AML Cohort — Male | — | — | 40 | 31 | 71 |
| Ethnicity (NIH/OMB)(Participants) | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone | Total |
|---|---|---|---|---|---|
| MDS Cohort — Hispanic or Latino | 5 | 2 | — | — | 7 |
| MDS Cohort — Not Hispanic or Latino | 30 | 33 | — | — | 63 |
| MDS Cohort — Unknown or Not Reported | 7 | 7 | — | — | 14 |
| AML Cohort — Hispanic or Latino | — | — | 6 | 3 | 9 |
| AML Cohort — Not Hispanic or Latino | — | — | 39 | 41 | 80 |
| AML Cohort — Unknown or Not Reported | — | — | 19 | 21 | 40 |
| Race/Ethnicity, Customized(Participants) | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone | Total |
|---|---|---|---|---|---|
| MDS Cohort — American Indian or Alaska Native | 0 | 0 | — | — | 0 |
| MDS Cohort — Asian | 2 | 1 | — | — | 3 |
| MDS Cohort — Black or African American | 1 | 0 | — | — | 1 |
| MDS Cohort — Native Hawaiian or Other Pacific Islander | 0 | 0 | — | — | 0 |
| MDS Cohort — White | 30 | 33 | — | — | 63 |
| MDS Cohort — Not Collected or Reported | 7 | 5 | — | — | 12 |
| MDS Cohort — Other | 2 | 3 | — | — | 5 |
| AML Cohort — American Indian or Alaska Native | — | — | 0 | 0 | 0 |
| AML Cohort — Asian | — | — | 0 | 0 | 0 |
| AML Cohort — Black or African American | — | — | 0 | 1 | 1 |
| AML Cohort — Native Hawaiian or Other Pacific Islander | — | — | 0 | 0 | 0 |
| AML Cohort — White | — | — | 45 | 42 | 87 |
| AML Cohort — Not Collected or Reported | — | — | 18 | 21 | 39 |
| AML Cohort — Other | — | — | 1 | 1 | 2 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone | Total |
|---|---|---|---|---|---|
| MDS Cohort — 0 - Fully active | 17 | 18 | — | — | 35 |
| MDS Cohort — 1 - Restricted but ambulatory | 20 | 20 | — | — | 40 |
| MDS Cohort — 2 - Ambulatory but unable to work | 3 | 4 | — | — | 7 |
| MDS Cohort — 3 - Limited self-care | 0 | 0 | — | — | 0 |
| MDS Cohort — 4 - Completely Disabled | 0 | 0 | — | — | 0 |
| MDS Cohort — Missing | 2 | 0 | — | — | 2 |
| AML Cohort — 0 - Fully active | — | — | 19 | 26 | 45 |
| AML Cohort — 1 - Restricted but ambulatory | — | — | 40 | 32 | 72 |
| AML Cohort — 2 - Ambulatory but unable to work | — | — | 5 | 7 | 12 |
| AML Cohort — 3 - Limited self-care | — | — | 0 | 0 | 0 |
| AML Cohort — 4 - Completely Disabled | — | — | 0 | 0 | 0 |
| AML Cohort — Missing | — | — | 0 | 0 | 0 |
| Revised International Prognostic Scoring System (IPSS-R) Cytogenetic Risk Groups (MDS Cohort)(Participants) | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone | Total |
|---|---|---|---|---|---|
| Very good | 1 | 1 | — | — | 2 |
| Good | 10 | 10 | — | — | 20 |
| Intermediate | 9 | 8 | — | — | 17 |
| Poor | 8 | 9 | — | — | 17 |
| Very Poor | 14 | 14 | — | — | 28 |
| Cytogenetic Risk Classifications (AML Cohort)(Participants) | MDS: Azacitidine + Durvalumab | MDS: Azacitidine Alone | AML: Azacitidine + Durvalumab | AML: Azacitidine Alone | Total |
|---|---|---|---|---|---|
| Better risk | — | — | 0 | 0 | 0 |
| Intermediate risk | — | — | 25 | 26 | 51 |
| Poor risk | — | — | 16 | 16 | 32 |
| Missing | — | — | 23 | 23 | 46 |
Showing the first 100 of 103 sites across 12 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2016 to primary completion in Dec 2018, 30 months.
Results were first posted in May 2020, 1 year 4 months after primary completion.
Of 57 industry-sponsored phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 55. This study's 30 months is below that.
Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Durvalumab